We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Treatment of Akata EBV-Positive Cells with Doxorubicin Causes More EBV Reactivation than Treatment with Etoposide.
- Authors
Lima, Raquel T.; Seca, Hugo; Brás, Susana; Nascimento, Maria S.J.; Vasconcelos, M. Helena
- Abstract
Background/Aims: EBV has been associated with Burkitt lymphoma (BL). It establishes a latent infection but its reactivation has been observed in patients receiving long-term chemotherapy. The effect of doxorubicin on virus reactivation has been described previously, but the effect of etoposide or cytarabine on EBV reactivation has not been reported in the literature. The aim of this work was to carry out such a study. Methods: Akata EBV-positive cell lines were treated with etoposide, doxorubicin or cytarabine. Viable cells were analyzed by trypan blue, programmed cell death by TUNEL assay, mRNA levels by RT-PCR and cellular or viral proteins by Western blot. Viruses were visualized by electron microscopy. Results: All of the studied drugs caused cell death by apoptosis. Comparing the effect of etoposide and doxorubicin (at their IC50) in the EBV-positive cells, etoposide caused less EBV reactivation than doxorubicin. Cytarabine apparently did not reactivate EBV. Conclusion: When treating Akata EBV-positive cells with the respective IC50 of the following drugs, etoposide induced less EBV reactivation than doxorubicin, and cytarabine apparently did not induce EBV reactivation. Copyright © 2011 S. Karger AG, Basel
- Subjects
TREATMENT of Epstein-Barr virus diseases; DOXORUBICIN; ETOPOSIDE; LYMPHOMAS; CANCER chemotherapy; REVERSE transcriptase polymerase chain reaction; VIRAL proteins; WESTERN immunoblotting
- Publication
Chemotherapy (0009-3157), 2011, Vol 57, Issue 3, p195
- ISSN
0009-3157
- Publication type
Article
- DOI
10.1159/000323627